We report three cases of massive chest wall plasmacytoma, each greater than 10 cm in diameter, without evidence of overt myeloma, whom we treated with a combination of VAD chemotherapy consolidated by highdose melphalan and autologous peripheral blood stem cell transplantation and radical radiotherapy. All three patients completed all components of their therapy without experiencing any major side effects and one patient has had a durable remission. The other two patients have had disease progression but at sites other than the original tumour.
melphalan; myeloma; high dose therapy Chest wall plasmacytomas are not unusual in multiple myeloma, reflecting the ease with which extraosseous extension occurs with rib deposits. Occasionally these masses become very large with no evidence of disseminated disease elsewhere. It has previously been noted that those patients whose tumour measured 5 cm or more in diameter at diagnosis had a higher risk of treatment failure when managed with local radiotherapy alone. 1 Although plasmacytomas are generally responsive to VAD-based treatment 2 followed by radical radiotherapy (35-40 Gy in 20 fractions over 4 weeks), larger tumours of greater than 10 cm diameter are difficult to control with this approach. We describe three patients whom we treated with a combination of VAD chemotherapy consolidated by high-dose melphalan and autologous peripheral blood stem cell transplantation (PBSCT) and radical radiotherapy, one of whom had a durable remission.
Patients and methods
A 50-year-old man (patient 1) presented with a 2-week history of right shoulder discomfort and paraesthesiae affecting his right upper chest in June 1994. A CT scan of his chest revealed two very large soft tissue masses involving the right chest wall and extending into the lung; the larger of the two was 11 cm in diameter. Within the mass, the ribs were abnormal and destroyed. The medial border of the mass extended to lie adjacent to the right side of the upper thoracic vertebrae. CT guided biopsy of the mass demonstrated that this was a plasmacytoma. A 62-year-old man (patient 2) presented in April 1997 with weight loss and recurrent chest infections. Physical examination revealed a palpable swelling with dilated veins on his right chest wall. A chest X-ray demonstrated expansion and destruction of the right 7th and 8th ribs associated with a moderate pleural effusion, and a CT scan confirmed a mass measuring 13.5 Â 10 Â 15 cm (Figure 1 ) arising from the right lower chest wall. Biopsy showed this to be a plasmacytoma with k light chain restriction. The final patient (patient 3), a 51-year-old man, presented with chest pain in February 1998 and was found to have a large tumour measuring 12 Â 9 Â 7 cm involving his right 3rd rib. Biopsy showed a plasmacytoma. The laboratory features of each of these patients at diagnosis are given in Table 1 . Only patient 3 had an excess of plasma cells (7%) in the bone marrow.
The plan for all three patients was to debulk the tumour with VAD chemotherapy 2 followed by high-dose melphalan supported by PBSC and to treat the residual mass with radical radiotherapy as the final treatment ( Table 2) . One of the objectives of the initial chemotherapy and high-dose therapy was to reduce the field size for radiotherapy and thus minimise toxicity to normal lung tissue. In patient 3, the treatment plan was modified due to a poor response to VAD and the radiotherapy was given prior to the high-dose melphalan for symptom control. Following their VAD chemotherapy, patients underwent stem cell mobilisation using cyclophosphamide 3 g/m 2 followed by autologous PBSCT using melphalan 200 mg/m 2 as conditioning chemotherapy. All patients completed the components of the treatment plan without any major side effects.
Results
Currently, patient 2 remains well with normal blood counts, calcium and renal function and no detectable paraprotein at 5 years following completion of therapy.
He has shown no evidence of local disease recurrence although he has a residual calcified mass measuring 10 Â 6 Â 13 cm. Patient 1 was assessed to be in complete remission post transplant with no residual mass on CT scan and no detectable paraprotein by immunofixation. However, in July 1995, 8 months post transplant, he presented with cervical lymphadenopathy, and biopsy indicated the development of an immunoblastic high-grade lymphoma composed of sheets of plasmacytoid cells again showing l light chain restriction. He was treated with further chemotherapy followed by a second autologous stem cell transplant using stem cells harvested in 1994, but he rapidly relapsed and died of progressive disease in August 1997.
Discussion
Published data on prognostic factors associated with poor overall survival or progression to myeloma for patients with solitary plasmacytoma include advanced age, axial lesions, osteopenia, low levels of uninvolved immunoglobulins, high paraprotein levels and persistence of paraprotein after radiotherapy. [8] [9] [10] . Relatively few studies have addressed the impact of tumour size on treatment outcome for plasmacytoma. Holland et al 7 reported that the size of the primary lesion had prognostic significance in predicting conversion to multiple myeloma. In this study of 46 cases of solitary plasmacytoma treated with radiotherapy, the median lesion size for those patients in whom disease progression to myeloma occurred was 7 cm, compared to 3.75 cm for those remaining myeloma-free. Furthermore, 9/11 (82%) of those patients with conversion to myeloma had lesions that were 5 cm or larger, compared to 5/18 patients (28%) who remained myeloma-free. 7 In a second report of 46 patients with solitary plasmacytoma treated with radiotherapy alone, Tsang et al noted that those patients whose tumour measured 5 cm or more in diameter at diagnosis had a higher risk of treatment failure. 1 In particular, 5/6 patients with tumours of this size treated with p35 Gy experienced failure of local control. Four of these, developed multiple myeloma whereas this radiation dose was found to be adequate for smaller plasmacytomas, with only 1/14 patients experiencing local treatment failure. Radiotherapy is the recommended primary treatment modality for solitary plasmacytomas. Some studies have shown no benefit from adjuvant chemotherapy 7 although other reports have suggested that this may prevent progression of solitary plasmacytoma to myeloma following radiotherapy. 8 The published data relating to the role of high-dose therapy are restricted to a few isolated case reports of patients with multiple plasmacytomas, which do not address the issue of tumour size. 9, 10 In the light of studies demonstrating that for patients who present with massive plasmacytomas, radiotherapy alone is unlikely to result in local control or cure, we employed a treatment strategy incorporating the use of initial VAD chemotherapy, usually reserved for the treatment of multiple myeloma, followed by high-dose chemotherapy and finally radiotherapy to encompass any residual mass. This treatment was well tolerated and produced a durable remission in one patient. The other two patients relapsed in new sites not previously involved and one of these patients had evidence of dissemination with a low-level plasma cell infiltrate at diagnosis. We conclude that this approach is feasible and may result in long-term disease control in a proportion of patients.
